Results 1 to 10 of about 24,787 (310)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis [PDF]
New England Journal of Medicine, 2016 BACKGROUND Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis ...
Thomas Bieber +2 more
exaly +3 more sources
Dupilumab for bullous pemphigoid with intractable pruritus [PDF]
, 2019 Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Eichenfield, Dawn Z +2 more
core +2 more sources
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis [PDF]
New England Journal of Medicine, 2017 Bolanle Akinlade
exaly +3 more sources
Reactions Weekly, 2020 Ein neues Biologikum, das zur systemischen Behandlung der atopischen Dermatitis eingesetzt werden kann. Dupilumab ist bisher nicht direkt mit anderen systemischen Therapien verglichen worden und verursacht sehr häufig Augensymptome ...
+7 more sources
Clinical and Translational Allergy, 2023 Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten +13 more
doaj +1 more source
Dupilumab-associated cicatrizing ocular disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be ...
Amit K. Reddy +4 more
doaj +1 more source
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
PLoS ONE, 2022 BackgroundDupilumab is a human antibody that blocks the signaling of both interleukin-4 and interleukin-13 receptors. It has been approved for the treatment of moderate-to-severe atopic dermatitis.
Sunny Park +3 more
doaj +3 more sources
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. [PDF]
, 2020 Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on Staphylococcus aureus colonization and microbial diversity on the ...
Ardeleanu, Marius +16 more
core +2 more sources
Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
Journal of Dermatological Treatment, 2023 Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form ...
Shiyu Zhang +8 more
doaj +1 more source
Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
Scientific Reports, 2021 Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases ...
Sunny Park +6 more
doaj +1 more source